EXPRESSION OF VITAMIN D3 RECEPTOR IN TUMOR TISSUE AND RELATIONSHIP BETWEEN CLINICAL FEATURES, PROGNOSTIC INDICATORS AND EXPRESSION OF VITAMIN D3 RECEPTOR IN HODGKIN LYMPHOMA
DOI:
https://doi.org/10.46827/ejphs.v7i3.190Keywords:
Hodgkin lymphoma, vitamin D, vitamin D receptor, prognostic indicatorAbstract
Background and objectives: In our study, we aimed to investigate the expression of vitamin D receptor and the relationship between clinical features, prognostic indicators, and expression of vitamin D receptor in Hodgkin lymphoma. Materials and Methods: Pathology records and medical files of patients with Hodgkin lymphoma were evaluated. Forty-two tissue samples were analyzed retrospectively. Vitamin D receptor staining was performed with immunohistochemistry. The patients were divided into low, medium, and intense staining subgroups. The demographic data, clinical and biochemical values of patients were reviewed retrospectively, and the relationship between clinical features, prognostic indicators, and vitamin D receptor expressions were examined. Results: VDR staining was positive in Reed-Sternberg cells of all Hodgkin lymphoma patients. The cases were divided into three groups according to VDR staining intensity as low, medium and intense staining and compared with known clinical prognostic parameters. Only the presence of symptom B was statistically significantly different. Gender, bone marrow involvement, extralymphatic involvement, mediastinal mass, bulky mass, mean leukocyte count, and treatment response were associated with vitamin D receptor staining intensity, but they were statistically insignificant. Conclusion: Our study is the second study showing VDR in tumor Hodgkin lymphoma tumor tissues and is meant to be the first to evaluate its association with clinical and biochemical prognostic laboratory tests. Vitamin D receptor staining in all Hodgkin lymphoma patients led to the conclusion that VDR can be used in the histopathological differential diagnosis of HL. More studies are needed to assess and demonstrate the relationship between prognostic and diagnostic indicators and vitamin D receptor intensity of immunohistochemically detected VDR in tumor tissues of Hodgkin lymphoma. Also, further studies with serum vitamin D levels and other histologic subtypes can provide more reliable results.
References
Cui X, McGrath J, Thomas H, Burne H, Eyles D, 2021. Vitamin D and schizophrenia: 20 years on. Molecular Psychiatry 26: 2708-2720. doi: 10.1038/s41380-021-01025-0
Yang C, Patrick S, Leung P, Iannis E, 2013. Adamopoulos, and M. Eric Gershwin, The Implication of Vitamin D and Autoimmunity: a Comprehensive Review, Clin Rev Allergy Immunol. 45: 217–226. doi: 10.1007/s12016-013-8361-3
Jagannath V, Filippini G, Borges I, do Nascimento, Pietrantonj C, Robak E, 2018. Whamond L, Vitamin D for the management of multiple sclerosis, Cochrane Database Syst Rev. 2018: CD008422. doi:10.1002/14651858.CD008422
Moon S, Fryer A, Strange R, 2005. Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers, Mutation Research 571:207–219. doi: 10.1016/j.mrfmmm.2004.09.015
Kumagai T, O’Kelly J, Said J, 2003. Vitamin D2 Analog 19-nor-1,25-Dihydroxyvitamin D2: Antitumor Activity Against Leukemia, Myeloma, and Colon Cancer Cells, JNCI J Natl Cancer Inst: 95: 896-905. doi: 10.1093/jnci/95.12.896.
Purdue M, Freedman D, Gapstur S, 2010. Circulating 25-Hydroxyvitamin D and Risk of Non-Hodgkin Lymphoma Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, Am J Epidemiol 172:58–69. doi: 10.1093/aje/kwq117
Grant W, 2003. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res. 164:371–377. doi: 10.1007/978-3-642-55580-0_2
Rosen C, Adams J, Bikle D, Black D, Demay M, Manson J, 2012. The Nonskeletal Effects of Vitamin D: An Endocrine Society Scientific Statement. Endocrine Reviews; 33: 456.492. doi: org/10.1210/er.2012-1000
Krishnan A, Feldman D, 2011. Mechanisms of the anticancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol: 51: 311.336. doi: 10.1146/annurev-pharmtox-010510-100611.
Hickish T, Cunningham D, Colston K, 1993. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer: 68:668–672.
Wang K, Dong M, Sheng W, 2015. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer. Histopathology 67:386-97. doi: 10.1111/his.12663.
Ditsch N, Toth B, Mayr D, 2012. The association between vitamin D receptor expression and prolonged overall survival in breast cancer. J Histochem Cytochem 60:121-9. doi: 10.1369/ 002215541 1429155.
Singh K, Sonkar A, Saxena P, 2015. Evaluation of effect of Vitamin D levels and tumor Vitamin D receptor status as a risk factor and marker for therapeutic response Indian breast cancer patients. Journal of Clinical Oncology. doi:10.1200/jco.2015.33.15.
Renné C, Benz A, Hansmann M, 2012. Vitamin D3 receptor is highly expressed in Hodgkin’ s lymphoma, Renné et al. BMC Cancer 12:215. doi:10.1186/1471-2407-12-215
Linabery A, Erhardt E, Fonstad R, Ambinder R, Bunin G, Ross J, Grufferman S, 2014. Infectious, autoimmune and allergic diseases and risk of Hodgkin lymphoma in children and adolescents: a Children’s Oncology Group study. Int J Cancer 135:1454. doi: 10.1002/ijc.28785
Hasenclever D, Diehl V, Armitage J, Assouline D, Björkholm M, Brusamolino E, Hudson G, 1988. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 339:1506-14. doi: 10.1056/nejm19981119339210
Alexander F, Jarrett R, Lawrence D, Armstrong A, Freeland J, Gokhale D, Cartwright R, 2000. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 82:1117. doi: 10.1054/ bjoc.1999.1049
Guermazi A, Brice P, Kerviler E, Fermé, C, Hennequin C, Meignin V, Frija J, 2001. Extranodal Hodgkin Disease: Spectrum of Disease 1. Radiographics, 21, 161-179
Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, Bergmann, L, 1998. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9:1117–1122 1. doi: 10.1023/a:1008486928190
Young C, Young B, Smith S, 1998. Staging Hodgkin's disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imaging. 1998;1:161–164.
NCCN Guidelines Version 2.2014, Hodgkin Lymphoma, ‘Examples of Unfavorable Risk Factors for Stage I-II Hodgkin Disease’, HODG-A, www.nccn.org.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
